3D Delivery Technology1,2

See the 3D mesh delivery technology in action. Watch the video now.

Clindamycin is dissolved within this mesh2

  • Polymeric mesh with honeycomb-like structure

Benzoyl Peroxide Particles are micronized and suspended1,2

  • Polymeric mesh holds particles in place, ensuring a uniform distribution of active ingredients

Adapalene Particles are micronized and suspended1,2

Application Reminders for Patients3

Ensure your patients read the Instructions for Use before they start using CABTREO and each time before they get a refill.

Step 1:

Patients should wash their face with a gentle, mild cleanser before applying CABTREO.

Step 2:

Dispense one pea-sized amount onto finger.

Step 3:

Apply onto 6 areas of their face.

Step 4:

Patients may use a moisturizer to minimize irritation.

Please see the Instructions for Use included in the accompanying full Prescribing Information.

Substraction

Remind patients to avoid concomitant acne therapies.

Substraction

Remind patients to avoid concomitant acne therapies.

ONE SCRIPT. ONE 50G PUMP.
ONE APPLICATION A DAY.3

With one application a day, CABTREO can become a part of your patient’s daily routine.1

Actor portrayal of an acne patient who could be treated with CABTREO. Not an actual patient.

Not an actual patient.

LEARN ABOUT THE REFRIGERATED DISTRIBUTION PROCESS icon

LEARN ABOUT THE REFRIGERATED DISTRIBUTION PROCESS icon

See More

Important Safety Information AND INDICATION

CONTRAINDICATIONS

CABTREO is contraindicated in patients with:

  • known hypersensitivity to clindamycin, adapalene, benzoyl peroxide, any components of the formulation, or lincomycin.
  • history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
See Less

Important Safety Information AND INDICATION

CONTRAINDICATIONS

CABTREO is contraindicated in patients with:

  • known hypersensitivity to clindamycin, adapalene, benzoyl peroxide, any components of the formulation, or lincomycin.
  • history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported. If a serious hypersensitivity reaction occurs, discontinue CABTREO immediately and initiate appropriate therapy.

Colitis: Clindamycin can cause severe colitis, which may result in death. Discontinue CABTREO if diarrhea occurs.

Photosensitivity: CABTREO may increase sensitivity to ultraviolet light. Avoid or minimize exposure to sunlight and sunlamps. Wear sunscreen and protective clothing when sun exposure cannot be avoided.

Skin Irritation and Allergic Contact Dermatitis: Stinging/burning/pain, erythema, dryness, irritation, exfoliation, and dermatitis may occur with use of CABTREO and may necessitate discontinuation. Weather extremes, such as wind or cold, may be irritating to patients under treatment with CABTREO. Depending upon severity, patients can use a moisturizer, reduce frequency of application, or discontinue use. Avoid applying CABTREO to areas of broken, eczematous, or sunburned skin, and concomitant use with other potentially irritating topical products. Avoid use of “waxing” as a depilatory method on skin treated with CABTREO.

Use of CABTREO with concomitant topical acne therapy has not been evaluated.

ADVERSE REACTIONS

The most common adverse reactions (occurring in >1% of the CABTREO group and greater than the vehicle group) were application site reactions, pain, erythema, dryness, irritation, exfoliation, and dermatitis.

DRUG INTERACTIONS

Use CABTREO with caution in patients receiving neuromuscular blocking agents.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Indication

CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1% is indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older.

Please click here for full Prescribing Information.

References: 1. Stein Gold L, Baldwin H, Kircik LH, et al. Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase II study of the first triple-combination drug. Amer J Clin Dermatol. 2022;23(1):93-104. 2. Ortho Dermatologics. Data on file. 3. CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1% [prescribing information]. Bridgewater, NJ. Bausch Health US, LLC.